Gold nanoprisms as a hybrid in vivo cancer theranostic platform for in situ photoacoustic imaging, angiography, and localized hyperthermia
Name
12274_2016_Article_996.pdf
Size
2.96 MB
Format
Adobe PDF
Checksum (MD5)
bcc61640607dd588d88252a8ba048e88
Author(s)
Bao, Chenchen
Pan, Fei
Li, Chao
Zhang, Chunlei
Tian, Furong
Liang, Shujing
Cui, Daxiang
de la Fuente, Jesus M.
Osorio De Castro Conde, Joao
Date Issued
February 2016
Journal
Nano Research
Publisher
Tsinghua University Press
Citation
Bao, Chenchen, João Conde, Fei Pan, Chao Li, Chunlei Zhang, Furong Tian, Shujing Liang, Jesus M. de la Fuente, and Daxiang Cui. “Gold Nanoprisms as a Hybrid in Vivo Cancer Theranostic Platform for in Situ Photoacoustic Imaging, Angiography, and Localized Hyperthermia.” Nano Research 9, no. 4 (February 24, 2016): 1043–1056.
Version
Author's final manuscript
Abstract
The development of high-resolution nanosized photoacoustic contrast agents is an exciting yet challenging technological advance. Herein, antibody (breast cancer-associated antigen 1 (Brcaa1) monoclonal antibody)- and peptide (RGD)-functionalized gold nanoprisms (AuNprs) were used as a combinatorial methodology for in situ photoacoustic imaging, angiography, and localized hyperthermia using orthotopic and subcutaneous murine gastric carcinoma models. RGD-conjugated PEGylated AuNprs are available for tumor angiography, and Brcaa1 monoclonal antibody-conjugated PEGylated AuNprs are used for targeting and for in situ imaging of gastric carcinoma in orthotopic tumor models. In situ photoacoustic imaging allowed for anatomical and functional imaging at the tumor site. In vivo tumor angiography imaging showed enhancement of the photoacoustic signal in a time-dependent manner. Furthermore, photoacoustic imaging demonstrated that tumor vessels were clearly damaged after localized hyperthermia. This is the first proof-of-concept using two AuNprs probes as highly sensitive contrasts and therapeutic agents for in situ tumor detection and inhibition. These smart antibody/peptide AuNprs can be used as an efficient nanotheranostic platform for in vivo tumor detection with high sensitivity, as well as for tumor targeting therapy, which, with a single-dose injection, results in tumor size reduction and increases mice survival after localized hyperthermia treatment.
MIT Department
Institute for Medical Engineering and Science
Harvard University--MIT Division of Health Sciences and Technology
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s12274-016-0996-y
